Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 188Re-PSMA
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Telix Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Demerger
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
Details : Rhine Pharma has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, 99mTc and 188Re.
Brand Name : RHN001-Tx
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 22, 2024
Lead Product(s) : 188Re-PSMA
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Telix Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Demerger
LOOKING FOR A SUPPLIER?